Skip to main content
. 2020 Jun 17;146(8):2067–2075. doi: 10.1007/s00432-020-03286-8

Table 2.

Baseline characteristics of patients with CRPC treated with abiraterone, enzalutamide, docetaxel or watchful waiting

Treatment Abiraterone Enzalutamide Docetaxel Watchful waiting
n 249 184 1006 2149
Anti-androgens before CRPC (%) 114 (46.0) 81 (44.0) 397 (39.5) 788 (36.8)
Comorbidity score (%)
 0 168 (67.5) 107 (58.2) 703 (70.0) 1227 (57.1)
 1 43 (17.3) 38 (20.7) 185 (18.4) 496 (23.1)
 2 24 (9.6) 23 (12.5) 80 (8.0) 252 (11.7)
 3 6 (2.4) 6 (3.3) 22 (2.2) 86 (4.0)
 4 5 (2.0) 4 (2.2) 8 (0.8) 46 (2.1)
 5 0 (0.0) 2 (1.1) 3 (0.3) 13 (0.6)
 6 3 (1.2) 2 (1.1) 4 (0.4) 17 (0.8)
 7 0 (0.0) 1 (0.5) 0 (0.0) 5 (0.2)
 8 0 (0.0) 1 (0.5) 0 (0.0) 5 (0.2)
Bone metastases (%) 142 (87.7) 103 (87.3) 703 (91.1) 929 (81.7)
Lymph node metastases (%) 66 (80.5) 41 (83.7) 373 (82.5) 507 (76.6)
Visceral metastases (%) 8 (16.7) 8 (24.2) 57 (21.7) 52 (16.1)
WHO (%)
 1 37 (40.2) 26 (43.3) 222 (42.0) 360 (47.1)
 2 41 (44.6) 21 (35.0) 245 (46.3) 317 (41.5)
 3 14 (15.2) 13 (21.7) 62 (11.7) 87 (11.4)
Pain (%) 47 (42.0) 28 (37.8) 317 (49.2) 323 (31.0)
Opioid use (%) 22 (32.8) 9 (24.3) 120 (29.3) 113 (22.7)
Gleason > 7 (%) 143 (67.8) 105 (65.2) 591 (65.9) 998 (55.5)
Time to castration (median [range]) 11.17 [1.4, 192] 13.34 [1, 196] 10.12 [0.2, 172.7] 20.47 [0.3, 248.4]
Age (median [range]) 76.00 [46, 95] 77.00 [50, 94] 70.00 [46, 93] 78.00 [49, 99]
Weight (median [range]) 83.00 [52, 120] 86.00 [60, 120] 84.50 [48, 150] 81.00 [44, 118]
Hemoglobulin (median [range]) 8.00 [5.1, 9.6] 8.00 [4.7, 10.3] 8.00 [4.3, 10.2] 8.10 [3.9, 10.5]
Platelets (median [range]) 234.00 [37, 569] 228.50 [54, 473] 243.00 [0.4, 749] 233.00 [0.3, 714]
Lactate dehydrogenase (median [range]) 218.00 [72, 3179] 216.00 [98, 730] 232.00 [21, 4100] 218.00 [79, 4329]
Alkaline phosphatase(median [range]) 122.00 [41, 1673] 109.00 [38, 1263] 136.00 [34.8, 3457] 93.00 [21, 4315]
PSA (median [range]) 34.00 [0.1, 8730] 24.40 [0.1, 4150] 40.00 [0.0, 8700] 9.70 [0.1, 4034]